mk2 Biotechnologies, a peptide and protein production specialist for large-scale applications, and Sartorius Stedim Biotech Corporate Research, a leading technology and solutions provider to the biotech/biopharma industry, are happy to announce that they are joining forces to create the next-generation, low-cost biologics production platform. Integrating an intensified approach, the platform aims to make a groundbreaking step forward to facilitate sustainable and cost-efficient, large-scale production of high-efficacy biologics. The collaboration will pave new ways to meet the rising global bio-based API demands.